Monday, November 9, 2015
- 9:00AM-11:00AM
-
Abstract Number: 1701
Long Term Outcome of Total Hip Replacement in Patients with Ankylosing Spondylitis
Spondylarthropathies and Psoriatic Arthritis - Comorbidities and Treatment Poster II- 9:00AM-11:00AM
-
Abstract Number: 1446
Long-Term Effectiveness and Safety of Abatacept in Juvenile Idiopathic Arthritis: Interim Results from the Abatacept in JIA Registry
Pediatric Rheumatology - Clinical and Therapeutic Aspects Posters. Juvenile Arthritis and Miscellaneous Rheumatic Diseases- 9:00AM-11:00AM
-
Abstract Number: 1351
Long-Term Efficacy of Latent Tuberculosis Infection Screening in Juvenile Idiopathic Arthritis Patients Prior to Anti-TNF Treatment in an Endemic Area
Infection-related Rheumatic Disease: Poster Session- 9:00AM-11:00AM
-
Abstract Number: 1816
Long-Term Outcome of Tacrolimus Therapy As a Maintenance Strategy in Patients with Lupus Nephritis
Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session II- 9:00AM-11:00AM
-
Abstract Number: 1633
Long-Term Radiographic and Patient-Reported Outcomes Based on Clinical Disease Activity Index Responses with Tofacitinib at 6 Months
Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster II- 9:00AM-11:00AM
-
Abstract Number: 1649
Long-Term Safety and Efficacy of Olokizumab in Patients with Moderate-to-Severe Rheumatoid Arthritis Who Have Previously Failed Anti-TNF Treatment
Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster II- 9:00AM-11:00AM
-
Abstract Number: 1795
Long-Term Safety and Efficacy of Tacrolimus for Lupus Nephritis Patients in Real World Setting -Results from 5 Year Interim Analysis of Post Marketing Surveillance of 1376 Patients in Japan-
Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session II- 9:00AM-11:00AM
-
Abstract Number: 1977
Long-Term Survival of Methotrexate in Giant Cell Arteritis Patients in Clinical Practice
Vasculitis Poster II- 9:00AM-11:00AM
-
Abstract Number: 1225
Long-Term Use of Biological Therapy and Discontinuation Rates in Rheumatoid Arthritis – Real World Patient Data
Epidemiology and Public Health Poster II: Pathogenesis and Treatment of Systemic Inflammatory Diseases- 9:00AM-11:00AM
-
Abstract Number: 1137
Low Molecular Weight Polyphenol Harpagoside Inhibits IL-1β-Induced Expression of IL-6 By Blocking the Expression and Activity of c-Fos in Primary Human Osteoarthritis Chondrocytes
Biology and Pathology of Bone and Joint Poster I: Osteoarthritis Pathogenesis- 9:00AM-11:00AM
-
Abstract Number: 1270
Low Socioeconomic Status As a Predictor of Long-Term Direct Medical Costs Following Diagnosis of Granulomatosus with Polyangiitis: A General Population-Based Cohort Study
Health Services Research Poster II (ACR): Healthcare Access, Patterns of Medication Use and Workforce Considerations- 9:00AM-11:00AM
-
Abstract Number: 1777
Lymphocyte Depletion, Recovery and Efficacy in NZBWF1 Lupus Mice Following Continuous or Intermittent Dosing Regimen of Venetoclax (ABT-199), a Potent and Selective BCL-2 Inhibitor
Systemic Lupus Erythematosus - Animal Models Poster II- 9:00AM-11:00AM
-
Abstract Number: 1913
Lysyl Oxidase Induces Fibrosis Via Upregulation of IL-6 and Serves As a Biomarker to Monitor Response to Therapy
Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Pathogenesis, Animal Models and Genetics Poster I